John Gray - Vertex Pharmaceuticals Senior Vice President Genetic Therapies

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 35px;;'>VRT</div>
VRTX -- USA Stock  

 Earnings Call  This Week

We currently do not have informatin regarding John Gray. This executive tanure with Vertex Pharmaceuticals Incorpor is not currenlty determined.
Age: 53  President Since 2019      
617 341-6100

Management Efficiency

The company currently holds 649.8 M in liabilities with Debt to Equity (D/E) ratio of 12.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals has Current Ratio of 3.37 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Alok SonigDr Reddys Laboratories Ltd
John HendricksonPerrigo Company Plc
Grainne QuinnPerrigo Company Plc
Svend AndersenPerrigo Company Plc
Ganadhish KamatDr Reddys Laboratories Ltd
Umang VohraDr Reddys Laboratories Ltd
James DillardPerrigo Company Plc
Andrew FentonZoetis
Thomas FarringtonPerrigo Company Plc
Joseph LaRosaRegeneron Pharmaceuticals
Jatin ShahPerrigo Company Plc
John WesolowskiPerrigo Company Plc
Catherine KnuppZoetis
Clinton LewisZoetis
Cartikeya ReddyDr Reddys Laboratories Ltd
Saumen ChakrabortyDr Reddys Laboratories Ltd
James MichaudPerrigo Company Plc
Heidi ChenZoetis
Marion McCourtRegeneron Pharmaceuticals
Stefan WeiskopfZoetis
Christopher FenimoreRegeneron Pharmaceuticals

Entity Summary

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2500 people.Vertex Pharmaceuticals Incorpor (VRTX) is traded on BATS Exchange in USA and employs 2,500 people.

Vertex Pharmaceuticals Leadership Team

William Young, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
John Gray, Senior Vice President Genetic Therapies
Margaret McGlynn, Independent Director
Sangeeta Bhatia, Director
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Paul Silva, Senior Vice President Corporate Controller
David Altshuler, Independent Director
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
David Greenway, Director
Charles Wagner, CFO, Executive Vice President
Bruce Sachs, Co-Lead Independent Director
Lloyd Carney, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Charles Milstein, Executive Vice President Chief Legal and Administrative Officer
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Return On Equity0.22
Return On Asset0.0017
Profit Margin0.31
Operating Margin25.01
Current Valuation53.1 B
Shares Outstanding257.15 M
Shares Owned by Insiders0.09
Shares Owned by Institutions98.70